Skip to main navigation

Immunocore

Immunocore

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

Primary Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Document & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact Us

News Releases

Breadcrumb

  1. Home /
  2. Investor Relations /
  3. News & Events /
  4. News Releases
9 December 2019
Immunocore announces dosing of first patient with third ImmTAC® bispecific
11 November 2019
New Data Uncover Deeper Insight into Tebentafusp (IMCgp100) Clinical Activity in Patients with Advanced Melanoma, Including Uveal
31 October 2019
Immunocore to Spotlight ImmTAC® Platform Research at 2019 SITC Annual Conference
18 July 2019
Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma
16 July 2019
Detailed Review of Tebentafusp (IMCgp100) in Metastatic Uveal Melanoma Published in Issue of Cancers
3 June 2019
New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma
30 May 2019
Immunocore to present at the Jefferies 2019 Global Healthcare Conference in New York
16 May 2019
Immunocore to Present New Tebentafusp (IMCgp100) Data in Advanced Melanoma at Upcoming 2019 ASCO Annual Meeting
13 May 2019
Immunocore Launches Campaign to Educate Physicians on Rare Eye Cancer
7 May 2019
Immunocore appoints Dr Mohammed Dar as Head of Clinical Development and Chief Medical Officer

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Next page next ›
  • Last page last »
Displaying 71 - 80 of 164

Site - Shareholder Tools

Print Page
Email Alerts
RSS Feeds
Email Page

Immunocore

Immunocore

Site - Footer Social

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • News
  • Careers
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2023 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd